Literature DB >> 924691

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France.

N Breslow, C W Chan, G Dhom, R A Drury, L M Franks, B Gellei, Y S Lee, S Lundberg, B Sparke, N H Sternby, H Tulinius.   

Abstract

A world-wide comparative study of the frequency and characteristics of latent carcinoma of the prostate was undertaken in seven areas, using standardized methods and "blind" microscopic evaluation in order to reduce selection and observer bias. The morphological features of 350 latent carcinomas found in 1,327 prostates were examined. Two Chinese populations, from Hong Kong and Singapore, showed a low frequency of latent carcinoma in comparison with western Europeans in Sweden and the Federal Republic of Germany and negroes from Jamaica; an intermediate position was found for Israelis and black Ugandans. The frequency of small latent carcinomas was about 12% in all the areas investigated and did not vary with age. Rates for larger latent carcinomas increased sharply with age ans showed an area-to-area variation resembling that of clinical carcinoma of prostate. The small carcinomas were almost exclusively situated in the outer half of the prostate and latent carcinomas of all sizes were evenly distributed between the anterior and posterior halves of the prostate and the right and left sides of the outer prostatic shell. Certain disagreements in diagnosis were noted when the sections from each area were evaluated independently by a different pathologist. Most of these disagreements were resolved by re-reading the sections; their occurrence had no significant effect on the geographical comparisons.

Entities:  

Mesh:

Year:  1977        PMID: 924691     DOI: 10.1002/ijc.2910200506

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

1.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Dietary fat, fatty acids and prostate cancer.

Authors:  D P Rose; J M Connolly
Journal:  Lipids       Date:  1992-10       Impact factor: 1.880

3.  Dietary folate deficiency blocks prostate cancer progression in the TRAMP model.

Authors:  Gaia Bistulfi; Barbara A Foster; Ellen Karasik; Bryan Gillard; Jeff Miecznikowski; Vineet K Dhiman; Dominic J Smiraglia
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

4.  Complementary medicine for prostate cancer: effects of soy and fat consumption.

Authors:  M A Moyad; W A Sakr; D Hirano; G J Miller
Journal:  Rev Urol       Date:  2001

Review 5.  Cancer screening in renal transplant recipients: what is the evidence?

Authors:  Germaine Wong; Jeremy R Chapman; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

6.  Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

Authors:  P Lenner; H Jonsson; O Gardfjell
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

7.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

8.  Trends in prostate cancer in the Republic of Ireland 1954-81.

Authors:  J P Corridan; M A Moran; J W Magner
Journal:  Ir J Med Sci       Date:  1987-01       Impact factor: 1.568

9.  Migration and prostate cancer: an international perspective.

Authors:  F F Angwafo
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

10.  Prostate cancer screening (United States).

Authors:  J W Waterbor; A J Bueschen
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.